FDA Approves Two New Treatment Options for Adult Pulmonary Hypertension Patients
The FDA approved riociguat (Adempas) for the treatment of adult patients with two types of pulmonary hypertension. According to the FDA, “It is intended for patients with chronic thromboembolic pulmonary hypertension (CTEPH) after surgery or patients who cannot undergo surgery, to improve their ability to exercise. Adempas is also indicated for patients with pulmonary arterial hypertension (PAH) of unknown causes, inherited or associated with connective tissue diseases, to improve their ability to exercise and to delay clinical worsening of their condition.” Read the full FDA statement.
< Back to Listings